文献速递神经肿瘤

内镜经蝶垂体腺瘤手术后并发症、再入院与再手术的发生率及预测因素

Incidence and predictors of complications, readmission, and reoperation following endoscopic transsphenoidal surgery for pituitary adenomas.
PubMed 文献 · J Neurosurg · 2026-07-24

90天再入院率10.2%、再手术率4.8%,延迟性低钠血症是再入院首位原因。肿瘤直径增大、质地坚韧、术中脑脊液漏及扩大入路是并发症预测因素。

要点

  • 90天再入院率10.2%,首位原因为延迟性低钠血症(4.2%)。
  • 90天再手术率4.8%,首位原因为脑脊液漏(2.5%)。

核心结论

  • 内镜经蝶垂体腺瘤手术病死率与并发症率较低,但多种并发症仍可发生。
  • 避免内分泌相关再入院可降低再入院与再手术频率。

研究设计与样本

  • 回顾性队列研究,纳入2011年5月至2024年9月单中心693例组织学确诊垂体腺瘤患者共709次内镜经蝶手术。

主要发现

  • 肿瘤中位直径24 mm(IQR 17–32 mm),大腺瘤占93%,MRI海绵窦侵犯占32.2%,全切率63.5%,中位住院3天。
  • 手术并发症:脑脊液漏4.2%、鼻出血2.7%、颅神经麻痹1.0%、视力恶化1.0%、脑膜炎1.0%、卒中0.8%、脑积水0.7%、血肿0.6%、鼻窦炎0.6%、腹部血肿或感染0.4%、颈动脉损伤0.1%、死亡0.3%。
  • 医疗并发症:暂时性尿崩症8.7%、永久性尿崩症2.4%、菌血症/脓毒症0.7%、肺炎0.3%、深静脉血栓/肺栓塞0.1%。
  • 90天再入院率10.2%,原因包括延迟性低钠血症4.2%、脑脊液漏1.8%、感染1.1%、鼻出血0.7%、低皮质醇血症0.1%。
  • 90天再手术率4.8%,原因包括脑脊液漏2.5%、残留肿瘤1.3%、视力恶化0.6%、感染0.6%、血肿0.3%。

关键数值与推荐

  • 并发症预测因素包括肿瘤直径增大、肿瘤质地坚韧、术中脑脊液漏及采用扩大入路。
  • 从队列前半段至后半段,术后脑脊液漏(5.1% vs 3.4%)、再入院(11.4% vs 9.1%)与再手术(5.7% vs 4.0%)均有下降,但未达统计学显著。

临床怎么用

  • 可依据肿瘤直径、质地、术中脑脊液漏及入路类型对患者进行并发症风险咨询。
  • 术后应重点监测并管理延迟性低钠血症,以减少再入院。

局限性

  • 单中心回顾性研究设计,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Endoscopic transsphenoidal surgery (eTSS) is a common neurosurgical procedure used to treat pituitary adenomas (PAs). The authors evaluated the incidence of complications, early readmission, and early reoperation following eTSS for PAs and identified clinical, surgical, and tumor characteristics predictive of these outcomes. METHODS: The data of all patients with histologically confirmed PAs who underwent eTSS at the authors' institution between May 2011 and September 2024 were retrospectively reviewed. Thirty-day postoperative complications were grouped into surgical and medical categories. Early readmission and early reoperation were defined as occurring within 90 days of discharge and surgery, respectively. RESULTS: A total of 709 endoscopic transsphenoidal operations (655 direct and 54 extended approaches) were performed in 693 patients. The median tumor diameter (IQR) was 24 (17-32) mm, and 656 cases (93%) were macroadenomas. Cavernous sinus invasion on MRI was noted in 32.2% of cases. Fifteen percent were reoperations. Gross-total resection was achieved in 63.5% of patients, and the median length of stay was 3 days. Surgical complications included postoperative CSF leakage (4.2%), epistaxis (2.7%), cranial nerve palsy (1.0%), worsened vision (1.0%), meningitis (1.0%), stroke (0.8%), hydrocephalus (0.7%), hematoma (0.6%), sinusitis (0.6%), abdominal hematoma or infection (0.4%), carotid artery injury (0.1%), and death (0.3%). Medical complications included transient diabetes insipidus (8.7%), permanent diabetes insipidus (2.4%), bacteremia/sepsis (0.7%), pneumonia (0.3%), and deep venous thrombosis/pulmonary embolism (0.1%). Early readmission and early reoperation were observed in 10.2% and 4.8% of cases, respectively. The most common reasons for early readmission were delayed hyponatremia (4.2%), CSF leakage (1.8%), infection (1.1%), epistaxis (0.7%), and hypocortisolemia (0.1%), while the most common reasons for early reoperation were CSF leakage (2.5%), residual tumor (1.3%), worsened vision (0.6%), infection (0.6%), and hematoma (0.3%). Predictors of complications included increasing tumor diameter, firm tumor consistency, the presence of an intraoperative CSF leak, and use of an extended approach. While not statistically significant, rates of postoperative CSF leakage (5.1% vs 3.4%), early readmission (11.4% vs 9.1%), and early reoperation (5.7% vs 4.0%) decreased from the first half of the cohort to the second half of the cohort. CONCLUSIONS: Endoscopic TSS for PAs is associated with low morbidity and mortality, although a number of complications are possible. Readmission and reoperation following eTSS occur less frequently when endocrine readmissions can be averted. The results of this study provide information on the risks associated with eTSS and serve as a guide for neurosurgeons to counsel patients undergoing this procedure.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Pham J, Cote DJ, Kang KM, et al. Incidence and predictors of complications, readmission, and reoperation following endoscopic transsphenoidal surgery for pituitary adenomas. J Neurosurg. 2026. PMID: 42497462. doi:10.3171/2026.2.JNS252393

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。